AIM
PCRX icon

Arcadia Investment Management’s Pacira BioSciences PCRX Stock Holding History

Arcadia Investment Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-633
Closed -$21K – 408
2016
Q2 		$21K Buy
+633
New +$31.1K 0.01% 328

Other funds holding PCRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arcadia Investment Management's PCRX Position: Q3 2016 in Review

Arcadia Investment Management sold out of Pacira BioSciences (PCRX) in Q3 2016, closing a stake of 633 shares — an estimated $21K sold.

Arcadia Investment Management first reported a position in PCRX in Q2 2016 and held it in 1 quarter. The position peaked at $21K in Q2 2016. 180 funds tracked by Wall St. Rank hold PCRX as of Q3 2016.

  • Arcadia Investment Management reported no remaining Pacira BioSciences position as of Q3 2016 after selling out during the quarter.
  • Arcadia Investment Management sold 633 Pacira BioSciences shares in Q3 2016, an estimated $21K.
  • Arcadia Investment Management first reported a position in Pacira BioSciences in Q2 2016 and held it in 1 quarter.
  • Arcadia Investment Management's Pacira BioSciences position peaked at $21K in Q2 2016.
  • 180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2016.

Based on Arcadia Investment Management's 13F filing for Q3 2016, filed 26 Oct 2016.